BioCentury
ARTICLE | Company News

AveXis, ReGenX deal

April 7, 2014 7:00 AM UTC

ReGenX granted AveXis exclusive, worldwide rights to develop and commercialize products using ReGenX's NAV rAAV9 vectors to treat spinal muscular atrophy (SMA) in humans. ReGenX will receive an undisclosed upfront payment and be eligible for undisclosed milestones, plus royalties on net sales of products incorporating the vectors. This quarter, AveXis plans to begin Phase I testing of its gene therapy, dubbed chariSMA, for infants with SMA. AveXis said NAV rAAV9 is one component of chariSMA. ...